Biotechnology

Wednesday Nov 15, 2023 - 10:08 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2023 Financial Report, Operational Update

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for artificial intelligence (“AI”), is reporting its financial and operational results for the third quarter ended Sept. 30, 2023. Highlights of the report include the publication of a foundational study demonstrating the ability…

Tuesday Nov 14, 2023 - 2:26 pm

InvestorNewsBreaks – SOHM Inc. (SHMN) Unveils New Suite of SOHM Nutrients’ Brand Chewables

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, has announced a new suite of products in the vitamin gummies space. Provided by the SOHM OTC Self-Care business unit, the new line includes 13 new SOHM Nutrients’ Brand Chewables. The new suite of chewable products offers an array of key benefits, including bone and skin…

Tuesday Nov 14, 2023 - 1:23 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q1 Fiscal 2024 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today released financial results for the first quarter of the fiscal year 2024, which ended Sept. 30, 2023. “We are pleased with the continued advancements across our pharmaceutical programs and commercial operations. We are particularly excited with the recent candidate selection and official launch of…

Tuesday Nov 14, 2023 - 12:14 pm

InvestorNewsBreaks – Progressive Care Inc. (RXMD), NextPlat Corp. (NASDAQ: NXPL) Announce Strong Q3 2023 Results

Progressive Care (OTCQB: RXMD), a personalized health care services and technology provider, today announced financial results for its third quarter ended Sept. 30, 2023. Among the highlights, the company reported record third quarter revenues of $12 .4 million, a 22% increase in comparison to the prior year period, driven primarily by strong growth at its PharmcoRx pharmacies. “We are thrilled with our third quarter results…

Tuesday Nov 14, 2023 - 10:43 am

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Featured in Bell2Bell Podcast

Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Longeveron’s CEO Wa’el Hashad joined the program to introduce the company and its business model. “Longeveron is a cell therapy-based biotech company. It…

Monday Nov 13, 2023 - 9:50 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is reporting on data from a long-term study. According to the announcement, extended long-term, follow-up data from Longeveron’s ELPIS I trial of Lomecel-B(TM) for patients with hypoplastic left heart syndrome (“HLHS”) is being presented as a poster at…

Thursday Nov 09, 2023 - 3:31 pm

InvestorNewsBreaks – SOHM Inc.’s (SHMN) ABBIE Technology Poised to Make a Difference in the Lives of Millions

SOHM (OTC: SHMN), a global generic drug innovator, recently completed the acquisition of a disruptive stem cell technology ABBIE (A Binding Based Integrating Enzyme) and patents from CGA Intellectual Holdings Inc. “[The acquisition] will allow the company to create regenerative medicine and cosmeceutical products for commercialization during the next year. SOHM’s acquisition of ABBIE grants it the ability to edit genes of a large number…

Thursday Nov 09, 2023 - 11:29 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Scientific Advisory Board as It Advances Product Development, Clinical and Commercial Efforts

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced the expansion of its scientific advisory board (“SAB”) to include several leading cardiologists. New members include Charles L. Brown III, MD, CEO of the Piedmont Healthcare Physician Enterprise, Tony Das, MD, a nationally recognized board-certified interventional cardiology specialist,…

Thursday Nov 09, 2023 - 9:46 am

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CMO Featured in Latest Bell2Bell Podcast Release

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the spotlight during a recent episode of The Bell2Bell podcast. During the podcast, PaxMedica chief medical officer David Hough and host Stuart Smith discuss key company achievements, including the company’s recent meeting with the U.S. Food and Drug Administration (“FDA”). Highlights mentioned during the podcast include the discussion with the…

Wednesday Nov 08, 2023 - 3:21 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Combine to Transform Medicine Through AI and Biotherapeutics

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell and immunotherapy platforms that modulate immune responses against cancers and infectious disease, and GEDi Cube International Ltd., an AI medical technology company, recently entered a definitive agreement to combine in a stock-for-stock acquisition. “The combined company will feature two main divisions: the AI division and the immunotherapy division, according…

Wednesday Nov 08, 2023 - 10:49 am

InvestorNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) to Serve as Official Title Sponsor of ‘A Special Private Evening with Luke Bryan’

Safety Shot (NASDAQ: SHOT) today announced that it is the official title sponsor of Save Our Musicians event, “A Special Private Evening with Luke Bryan.” At the charity concert event taking place on Nov. 18, 2023, in Jupiter, Florida, country superstar and American Idol judge Luke Bryan will be performing to raise money for the arts in public schools. The concert follows a similar successful…

Tuesday Nov 07, 2023 - 1:35 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Granted 3rd US Patent on Novel VECG Platform

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced that the United States Patent and Trademark Office has granted a new patent on its VECG platform. Patent number 11,793,444, “Electrocardiogram Patch Devices and Methods,” describes methods and systems for remote detection and/or diagnosis of acute myocardial infarction…

Tuesday Nov 07, 2023 - 10:41 am

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Phase 2 Study Results Published in Peer-Reviewed Journal

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting that its phase 2 study research exploring the potential of low-dose suramin intravenous infusions as an autism spectrum disorder (“ASD”) treatment has been published. According to the announcement, the findings from the study were published in the “Annals of General Psychiatry.” The company noted that the research had been led…

Tuesday Nov 07, 2023 - 10:12 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today released its third quarter 2023 financial results and provided recent operating highlights for its ALS clinical program. Among the highlights, the company reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8(R) in the RESCUE ALS open-label extension trial.…

Tuesday Nov 07, 2023 - 9:30 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receive $900K IIA Grant for New CDMO Business Unit

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, has been named the recipient of a grant from the Israel Innovation Authority (“IIA”). According to the announcement, the IIA, which is publicly funded and part of Israel’s Ministry of Economy, approved a nondilutive grant covering 66%…

Monday Nov 06, 2023 - 10:07 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Status Report on NASDAQ Compliance

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, has received a letter from the NASDAQ Stock Market. Dated Nov. 1, 2023, the letter is regarding SCNI’s noncompliance with the market’s requirement to maintain a minimum bid price of $1 per share. According to the report, Scinai…

Thursday Nov 02, 2023 - 11:38 am

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD), Bourne Partners to Collaborate in Evaluating Future Monetization of Potential PRV

PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, is working with leading financial services firm Bourne Partners. Bourne Partners specializes in the pharma, pharma services and consumer health spaces. According to the announcement, the collaboration is an important step in PaxMedica's strategy to explore potential monetization of a Priority Review Voucher prior to filing the NDA for PAX-101 for the treatment…

Thursday Nov 02, 2023 - 10:14 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled for Nov. 5–7, 2023, in Miami. According to the announcement, the oral presentation is based on an abstract describing the phase 2 clinical study of investigational drug…

Tuesday Oct 31, 2023 - 1:27 pm

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q3 2023 Financial Report, Reports Possible Adjustment of Facility Terms by EIB

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, is reporting on its financial results for the third quarter ended Sept. 30, 2023; the report also included key business updates. Financial numbers to note in the report include R&D expenses of $1.13 million compared to $1.19 million for…

Tuesday Oct 31, 2023 - 12:58 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Third Quarter 2023 Results Conference Call

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, announced that it will hold a conference call on Tuesday, Nov. 14, 2023, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended Sept. 30, 2023. The company will also review recent announcements, ongoing initiatives and…

Tuesday Oct 31, 2023 - 11:36 am

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Acquires Research Assets to Accelerate PAX-101 NDA Submission

PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, today announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (“RLS”). The assets were previously dedicated to the study of suramin’s potential efficacy in treating acute kidney injury resulting from chronic kidney disease. According to the announcement, the newly acquired data from RLS will play a crucial…

Monday Oct 30, 2023 - 11:16 am

InvestorNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Announces Planned Launch of Its Highly Anticipated Wellness Beverage

Safety Shot (NASDAQ: SHOT) today announced the upcoming direct-to-consumer launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Beginning the first week of December 2023, the beverage will be available for retail purchase at www.DrinkSafetyShot.com and www.Amazon.com. In addition, the company plans to launch business-to-business sales of Safety Shot to…

Friday Oct 27, 2023 - 10:33 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Secures $5.2M in Private Placement and Preferred Investment Option Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that it has closed its offering for the issuance and sale of 3,012,049 pre-funded warrants and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per pre-funded and associated preferred…

Friday Oct 27, 2023 - 9:52 am

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on Publication of Low-Dose Suramin for ASD Research

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, announced that its groundbreaking research will be published in the “Annals of General Psychiatry,” an internationally recognized scientific psychiatry publication. The research was reported in a manuscript titled “Randomized clinical trial of low-dose suramin intravenous infusions for treatment of autism spectrum disorder,” which will be published by the psychiatry publication. Written by PaxMedica chief medical officer Dr. David…

Thursday Oct 26, 2023 - 12:18 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Clearing Path to Submit NDA for PAX-101

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, today announced the completion of a type-B meeting with the FDA. During the live meeting, the company discussed positive results of the recent data from its PAX-HAT-301 study of suramin in stage one human African sleeping sickness caused by trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated. According to the announcement, PaxMedica received constructive…

Wednesday Oct 25, 2023 - 11:56 am

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT) Granted Second U.S. Patent for JW-700 Treatment Designed for $1.5B Hair-Growth Market

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, announced a “significant milestone” in its development of treatments for androgenetic alopecia, or hair loss: the granting of a second U.S. patent issued for JW-700, a topical treatment designed to improve minoxidil’s efficacy. The patent was issued by the U.S. Patent and Trademark Office. The patent adds to the growing global intellectual property (“IP”) estate…

Wednesday Oct 25, 2023 - 10:01 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Agreements for Private Placement, Preferred Investment Options

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, has entered into a definitive agreement for the issue and sale of more than 3 million common shares, or prefunded warrants in lieu thereof. Specifically, the company agreed to a private placement of 3,012,049 common shares priced at $0.83 per share. In addition, the company…

Tuesday Oct 24, 2023 - 10:41 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Advance INM-901 Following Positive Proof-of-Concept Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced its selection of a lead Alzheimer’s disease drug candidate, named INM-901, following positive results from several proof-of-concept studies in a validated Alzheimer’s treatment model. InMed will be advancing cannabinoid analog INM-901 in its pharmaceutical drug development program. “The most recent studies of INM-901…

Tuesday Oct 24, 2023 - 10:35 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. The segment focuses on the company’s most recent announcement of its topline results from the CLEAR Mind phase 2a clinical trial of LGVN’s Lomecel-B(TM) for the treatment of mild…

Monday Oct 23, 2023 - 11:02 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Filing in Connection with Proposed Arrangement with Celly Nu

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions. Together with Celly Nutrition Corp. (“Celly Nu”), FSD Pharma today announced its filing on www.SEDARPlus.ca its management information circular and related materials in connection with the special meeting of FSD Pharma Securityholders (as defined in the company’s press release dated Oct. 5,…

Friday Oct 20, 2023 - 2:53 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”). “The Texas-based company has clinical trial sites operating in the U.S., Italy, France, Spain, and Switzerland, to evaluate Berubicin’s performance against standard of…

Friday Oct 20, 2023 - 2:00 pm

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Participating in Webinar Focused on Future Health Tech

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, will be spotlighted in webinar taking place today. The webinar is scheduled to start at 3 p.m. ET. Renovaro BioSciences CEO Mark Dybul will be featured in the webinar, which is titled “Future Health Tech: Challenges and Opportunities,” and will…

Thursday Oct 19, 2023 - 1:38 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured at this month’s Virtual Investor Ask the CEO Conference. CNS Pharmaceuticals CEO John Climaco is scheduled to participate in a live moderated webcast during the conference; the webcast is slated to start at 4 p.m. ET.…

Thursday Oct 19, 2023 - 11:44 am

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Spotlighted in Latest Episode of Bell2Bell Podcast

PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical company, was featured in the most recent release of the Bell2Bell podcast series. During the segment, PaxMedia CEO and chair Howard Weisman and PaxMedica corporate communications representative Buzz Woods provided an overview of the company’s latest accomplishments and future objectives with Bell2Bell host Stuart Smith. The trio discussed PaxMedia’s pioneering work in novel anti-purinergic drug therapies (“APT”) for…

Wednesday Oct 18, 2023 - 12:28 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Featured in Bell2Bell Podcast

PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical firm, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica’s CEO and Chairman Howard Weisman and Buzz Woods, from the company’s corporate communications department, joined the program to offer a compelling overview of the company’s recent achievements and future objectives. During…

Tuesday Oct 17, 2023 - 11:04 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced that it has innovated its investigational drug, CNM-Au8(R), with nanotechnology. Clene is evaluating CNM-Au8(R) for the treatment of neurodegenerative disease, and the innovation reflects the growing importance of nanotechnology in the drug space. The announcement noted that Clene’s nanotechnological approach was recently awarded…

Monday Oct 16, 2023 - 12:15 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in a recent article focused on glioblastoma, the most aggressive type of brain cancer. Noting that glioblastoma has an average survival of only 14 to 16 months after diagnosis, the article points out that currently, glioblastoma has no cure…

Monday Oct 16, 2023 - 11:11 am

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT) Announces MMA Superstar Jorge “Gamebred” Masvidal as Brand Ambassador

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, has sealed a deal with mixed martial arts (“MMA”) superstar Jorge Masvidal. The agreement calls for Masvidal to serve as brand ambassador for Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot announced that agreement after becoming a ring sponsor…

Monday Oct 16, 2023 - 9:35 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, closed on its previously announced registered direct offering. The offering was comprised of 2,424,243 shares of Class A common stock or common stock equivalents priced at $1.65 per share, or common stock equivalent. In addition, Longeveron issued unregistered…

Friday Oct 13, 2023 - 2:24 pm

InvestorNewsBreaks — Octane Selects IBN as Official Media Partner for Upcoming Medical Innovation Forum

Octane, a convening organization of the Southern California technology and medical technology business ecosystem, is partnering with IBN (“InvestorBrandNetwork”), a pioneering corporate communications firm and content distributor, to provide key communications and coverage of Octane’s Medical Innovation Forum. According to the announcement, IBN will serve as Official Media Partner for the event, with IBN’s InvestorWire serving as the Official NewsWire. The two-day forum is slated for…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions